Drug Profile
Taprenepag
Alternative Names: PF 4217329; PF-04217329; Taprenepag isopropylLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antiglaucomas
- Mechanism of Action Prostaglandin E EP2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 11 Aug 2011 Discontinued - Phase-II for Glaucoma in USA (Topical)
- 30 Aug 2010 Phase-II development is ongoing in USA
- 11 Mar 2008 Phase-II clinical trials in Glaucoma in USA (unspecified route)